Amplitude Vascular Systems (AVS), a company focused on treating severely calcified arterial disease with its Pulse IVL platform, has completed a $36 million Series B financing round.

Pulse IVL uses high-frequency hydraulic pulsatile pressure waves to treat arterial calcium. Using these waves to disrupt calcium means there’s no need for stiff emitter elements, the company said.

AVS touts the system as the only IVL catheter to use a non-compliant balloon, which offers maximum luminal gain with less vessel trauma. The company said the funding will support the U.S. peripheral launch as well as U.S. coronary and IDE trials for its Pulse Intravascular Lithotripsy (PIVL) device.

AVS started enrolling patients in its POWER PAD II U.S. IDE trial in October 2024. The 120-patient study will evaluate the technical and clinical success of the Pulse IVL system in treating patients with calcific femoropopliteal arteries. Enrollment is anticipated to be completed mid-year 2025.

“We are pleased to see strong, sustained investor excitement around this technology,” said Mark Toland, chairman of the board for AVS. “Intravascular lithotripsy now represents a large and well-proven therapy that demands new solutions for patients with severely calcified arterial disease. This investor confidence reflects accelerated execution of critical company milestones in 2024, including the initiation of our U.S. peripheral IDE. The commitment from our partners at BioStar Capital and Cue Growth Partners reinforces the great progress toward commercial approval with this technology in the IVL space.”

The funding will also support the company’s coronary U.S. IDE and U.S. carotid IDE trials, for which AVS is partnering with the Jacobs institute to help improve stroke treatment.